← 產業報告目錄
Rare Kidney Diseases Market Size, Share & Trends Analysis Report By Target Indication, By Type of Molecule (Small Molecules, Biologics, By Route of administration (Oral, Intravenous, Subcutaneous, Others), By End-User, By Distribution, By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-19頁數 190報告編號 INSIGHTACE-708aaa1ab7
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Rare Kidney Diseases Market on a global scale was estimated at USD 2.9 Billion in 2024 and is poised to attain USD 8.1 Billion by 2034, with a projected CAGR of 11.0% between 2025 and 2034.
At its core, Rare Kidney Diseases pertains to key industry insights & findings from the report:
The emergence of the rare kidney disease market is credited to the improved understanding and identification of these conditions, resulting in higher. Stakeholders across the healthcare landscape are mountingly turning to these solutions to meet contemporary demands.
The market's upward path is underpinned by mounting healthcare spending, technological evolution, and the mounting focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, underpinned by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Rare Kidney Diseases Market Snapshot
Chapter 4. Global Rare Kidney Diseases Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Clinical Trial/Pipeline Analysis
4.8. Competitive Landscape & Market Share Analysis
4.9. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Target Indication Estimates & Trend Analysis
5.1. by Target Indication & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Indication:
5.2.1. IgA Nephropathy
5.2.2. Lupus Nephritis
5.2.3. Focal Segmental Glomerular Sclerosis
5.2.4. Membranous Nephropathy
5.2.5. C3 Glomerulopathy
5.2.6. Cystinosis
5.2.7. Dense Deposit Disease
5.2.8. Distal Renal Tubular Acidosis
5.2.9. Fabry Disease
5.2.10. Refractory Gout
5.2.11. Atypical Hemolytic Uremic Syndrome
5.2.12. Others
Chapter 6. Market Segmentation 2: by Type of Molecule Estimates & Trend Analysis
6.1. by Type Of Molecule & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Molecule:
6.2.1. Small Molecules
6.2.2. Biologics
6.2.2.1. Monoclonal Antibody
6.2.2.2. Hormone
6.2.2.3. Recombinant Protein
6.2.2.4. Others
Chapter 7. Market Segmentation 3: by Route of Administration Estimates & Trend Analysis
7.1. by Route Of Administration & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route Of Administration:
7.2.1. Oral
7.2.2. Intravenous
7.2.3. Subcutaneous
7.2.4. Others
Chapter 8. Rare Kidney Diseases Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by Target Indication, 2021-2034
8.1.2. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by Type Of Molecule, 2021-2034
8.1.3. North America Rare Kidney Diseases Market revenue (US$ Million) by Route Of Administration, 2021-2034
8.1.4. North America Rare Kidney Diseases Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2021-2034
8.2.2. Europe Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2021-2034
8.2.3. Europe Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2021-2034
8.2.4. Europe Rare Kidney Diseases Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2021-2034
8.3.2. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2021-2034
8.3.3. Asia-Pacific Rare Kidney Diseases Market revenue (US$ Million) by Route Of Administration, 2021-2034
8.3.4. Asia Pacific Rare Kidney Diseases Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2021-2034
8.4.2. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2021-2034
8.4.3. Latin America Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2021-2034
8.4.4. Latin America Rare Kidney Diseases Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Target Indication, 2021-2034
8.5.2. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Type of Molecule, 2021-2034
8.5.3. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by Route of Administration, 2021-2034
8.5.4. Middle East & Africa Rare Kidney Diseases Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. GlaxoSmithKline
9.2.2. Recordati Rare Diseases
9.2.3. Amicus Therapeutics
9.2.4. Calliditas Therapeutics
9.2.5. Alexion Pharmaceuticals (A subsidiary of AstraZeneca)
9.2.6. Travere Therapeutics
9.2.7. Aurinia Pharmaceutical
9.2.8. Advicenne
9.2.9. Protalix Biotherapeutics
9.2.10. AstraZeneca
9.2.11. Chinook Therapeutics
9.2.12. Reata Pharmaceuticals
9.2.13. Roche
9.2.14. Novartis Pharmaceuticals
9.2.15. Merk & co
9.2.16. Apellis Pharmaceuticals
9.2.17. Omeros Corporation
9.2.18. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們